Motivation: The GlioGuard phantom was developed to address the challenges in achieving accurate, reproducible 2HG measurements enabling optimization of MRS sequences and validation of basis sets for glioma diagnostics. Goal(s): To evaluate GlioGuard's capability of measuring 2HG concentrations accurately by comparing optimized MRS sequences; PRESS and sLASER. Approach: GlioGuard used increasing 2HG concentrations in BRAINO solution, where the experiment was repeated with more Clariscan. MRS data from PRESS and sLASER sequences were acquired on a 3T scanner at Haukeland University Hospital. Data analysis involved metabolite quantification using Osprey 1. Results: sLASER provided more reproducible measurements, suggesting higher robustness for 2HG detection in clinical QA. Impact: GlioGuard standardizes 2HG detection in MRS, improving reliability and clinical relevance for glioma diagnostics. It provides cost-efficient, tumor-relevant compartments for accurate metabolite quantification, benefiting facilities without established MRS protocols or facilities focusing on optimization and quality assurance (QA).
Ager-Wick et al. (2025) studied this question.